Sanofi (France)
Parent Company
174/180 Avenue de France
Paris
Cedex
75013
France
Tel: 33-1-53-77-4000
Website: http://www.sanofi-synthelabo.fr/
1987 articles with Sanofi (France)
-
Press Release: Sanofi moves forward with EUROAPI listing on Euronext Paris
3/18/2022
A major milestone for EUROAPI, a leading European company dedicated to the development, production and marketing of active pharmaceutical ingredients*, as Sanofi’s Board of Directors unanimously proposed, on March 17th, to submit to its shareholders the distribution of circa 58% of the share capital of EUROAPI.
-
Seagen and Sanofi Announce Collaboration to Develop and Commercialize Multiple Novel Antibody-Drug Conjugates
3/16/2022
Seagen Inc. and Sanofi announced an exclusive collaboration agreement to design, develop, and commercialize antibody-drug conjugates for up to three cancer targets.
-
Press Release: Sanofi and Seagen announce collaboration to develop and commercialize multiple novel antibody-drug conjugates
3/16/2022
Sanofi and Seagen Inc. announced an exclusive collaboration agreement to design, develop, and commercialize antibody-drug conjugates for up to three cancer targets.
-
Sanofi secured a €300 million investment to advance the development of a subcutaneous formulation of Sarclisa, an anti-CD38 antibody for patients with multiple myeloma.
-
Sanofi announces €300 million collaboration with Blackstone Life Sciences to advance an innovative treatment for multiple myeloma
3/15/2022
Sanofi and Blackstone announced a strategic, risk-sharing collaboration under which funds managed by Blackstone Life Sciences will contribute up to €300 million to accelerate the global pivotal studies and the clinical development program for the subcutaneous formulation and delivery of the anti-CD38 antibody Sarclisa®, to treat patients with multiple myeloma.
-
Cambridge Crossing will enable innovative drug discovery platforms for chemistry, protein engineering, structural and synthetic biology, among other key modalities.
-
Across a range of indications, COVID-19-related and non-COVID-19-related, there was plenty of clinical trial news last week.
-
Shares of Sanofi took a hit in premarket trading after it announced its Phase II breast cancer study assessing an experimental oral SERD failed to hit the mark.
-
Efanesoctocog alfa met primary and key secondary endpoints in pivotal study in haemophilia A, demonstrating superiority to prior factor prophylaxis treatment
3/9/2022
Swedish Orphan Biovitrum AB and Sanofi announced positive top-line results from the pivotal XTEND-1 phase 3 study evaluating the safety, efficacy and pharmacokinetics of efanesoctocog alfa in previously treated patients ≥12 years of age with severe haemophilia A.
-
The XTEND-1 study showed that efanesoctocog alfa met its primary endpoint of clinically meaningful bleed prevention in people ages 12 years and older with severe hemophilia.
-
Efanesoctocog alfa met primary and key secondary endpoints in pivotal study in hemophilia A, demonstrating superiority to prior factor prophylaxis treatment
3/9/2022
Sanofi and Swedish Orphan Biovitrum AB announced positive topline results from the pivotal XTEND-1 Phase 3 study evaluating the safety, efficacy and pharmacokinetics of efanesoctocog alfa in previously treated patients ≥12 years of age with severe hemophilia A.
-
Sanofi recognized by S&P as one of the most sustainability-committed companies
3/8/2022
Sanofi was recognized as one of the most sustainability-committed companies in an ESG Evaluation performed by Standard & Poor’s Global Ratings.
-
Sanofi will more than $1 billion to build out its mRNA facilities and programs over the next several years. The site is expected to become operational in 2025.
-
Shares of Adagene Inc. are up more than 10% in premarket trading after the company announced a monoclonal and bispecific antibody collaboration with Sanofi valued at up to $2.5 billion.
-
On Sunday, Boehringer Ingelheim tweeted a message of support for Ukraine, and announced it was standing in solidarity with the embattled Eastern-European country.
-
The company is conducting analyses to understand safety data that had been gathered prior to the pausing of the three studies, NCT04605159, NCT04980391 and NCT05229068.
-
Late-breaking phase 3 data at 2022 AAAAI Annual Meeting show Dupixent® (dupilumab) significantly reduced itch and hives in patients with chronic spontaneous urticaria
2/26/2022
Detailed results from a Phase 3 trial showed that adding Dupixent® to standard-of-care antihistamines significantly reduced itch and hives at 24 weeks in biologic-naïve patients with chronic spontaneous urticaria compared to antihistamines alone in this investigational setting.
-
Sanofi and GSK to seek regulatory authorization for COVID-19 vaccine
2/23/2022
Sanofi and GSK announce that they intend to submit data from both their booster and Phase 3 efficacy trials as the basis for regulatory applications for a COVID-19 vaccine.
-
Public health officials begin to think we’ve turned the corner on the pandemic as new global cases drop 21% last week, the third consecutive week numbers and deaths have declined.
-
AstraZeneca and Sanofi secured accelerated authorization for respiratory syncytial virus (RSV) antibody nirsevimab from the European Medicines Agency.